Neil Bhowmick

List of Publications by Year
in descending order

143 papers	11,831 citations	47006 47 h-index	26613 107 g-index
145 all docs	145 docs citations	145 times ranked	16217 citing authors

#	Article	IF	Citations
1	A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth. Molecular Therapy, 2022, 30, 672-687.	8.2	11
2	Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e13-12.e22.	1.6	6
3	Plasma metabolomics to predict chemotherapy (CTX) response in advanced pancreatic cancer (PC) patients (pts) on enteral feeding for cachexia.. Journal of Clinical Oncology, 2022, 40, 600-600.	1.6	1
4	A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).. Journal of Clinical Oncology, 2022, 40, TPS636-TPS636.	1.6	0
5	Functional Diversity of Macropinocytosis. Sub-Cellular Biochemistry, 2022, 98, 3-14.	2.4	4
6	First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. Drugs, 2022, 82, 439-453.	10.9	3
7	Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer. Cancers, 2022, 14, 2491.	3.7	5
8	Metabolomics in advanced pancreatic cancer (PC) patients (pts) achieving weight stability on enteral feeding for cachexia.. Journal of Clinical Oncology, 2022, 40, e16291-e16291.	1.6	0
9	Fatty Acid Signaling Impacts Prostate Cancer Lineage Plasticity in an Autocrine and Paracrine Manner. Cancers, 2022, 14, 3449.	3.7	2
10	Bone marrow mesenchymal stem cells interact with head and neck squamous cell carcinoma cells to promote cancer progression and drug resistance. Neoplasia, 2021, 23, 118-128.	5.3	25
11	A Transcriptional Regulatory Loop of Master Regulator Transcription Factors, PPARG, and Fatty Acid Synthesis Promotes Esophageal Adenocarcinoma. Cancer Research, 2021, 81, 1216-1229.	0.9	41
12	Deregulated 14-3-3Î¶ and methionine adenosyltransferase Î±1 interplay promotes liver cancer tumorigenesis in mice and humans. Oncogene, 2021, 40, 5866-5879.	5.9	5
13	Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. OncoTargets and Therapy, 2021, Volume 14, 4819-4832.	2.0	11
14	Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification. Oncology, 2021, 35, 528-535.	0.5	0
15	Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells. Oncogene, 2020, 39, 1543-1556.	5.9	61
16	Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model. Cancers, 2020, 12, 2854.	3.7	17
17	The adaptor protein SHCA launches cancer invasion. Journal of Biological Chemistry, 2020, 295, 10560-10561.	3.4	4
18	Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?. Clinical Genitourinary Cancer, 2020, 18, 425-428.	1.9	7

#	Article	IF	Citations
19	Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer. Anticancer Research, 2020, 40, 1459-1462.	1.1	11
20	Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8515-8523.	7.1	12
21	Soluble CD105 is prognostic of disease recurrence in prostate cancer patients. Endocrine-Related Cancer, 2020, 27, 1-9.	3.1	13
22	COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocrine-Related Cancer, 2020, 27, R281-R292.	3.1	64
23	Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget, 2020, 11, 3621-3632.	1.8	29
24	Pushing the Heart Over a KLF(15). Journal of the American College of Cardiology, 2019, 74, 1820-1822.	2.8	0
25	Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma. Case Reports in Urology, 2019, 2019, 1-4.	0.3	17
26	NODâ€like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD. Hepatology, 2019, 70, 1582-1599.	7.3	53
27	In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cellâ€Based Drug Delivery. Stem Cells Translational Medicine, 2019, 8, 739-740.	3.3	1
28	A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Translational Medicine, 2019, 8, 441-449.	3.3	50
29	Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells. Cancer Letters, 2019, 449, 145-162.	7.2	16
30	ACTR-15. PHASE 1 TRIAL OF A KETOGENIC DIET IN PATIENTS RECEIVING STANDARD-OF-CARE TREATMENT FOR RECENTLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi15-vi15.	1.2	2
31	Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Oncogene, 2019, 38, 716-730.	5.9	64
32	Epigenetic changes in fibroblasts drive cancer metabolism and differentiation. Endocrine-Related Cancer, 2019, 26, R673-R688.	3.1	34
33	Visualization of Macropinocytosis in Prostate Fibroblasts. Bio-protocol, 2019, 9, .	0.4	5
34	3D Co-culture System of Mouse Prostatic Wild-type Fibroblasts with Human Prostate Cancer Epithelial Cells. Bio-protocol, 2019, 9, e3225.	0.4	0
35	Abstract 5164: Signaling crosstalk within prostate tumor microenvironment mediates castrate resistant disease progression. , 2019, , .		0
36	Regulation of inside-out Î²1-integrin activation by CDCP1. Oncogene, 2018, 37, 2817-2836.	5.9	17

#	Article	IF	Citations
37	Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptideâ€"Drug Conjugate. Journal of Medicinal Chemistry, 2018, 61, 2052-2061.	6.4	49
38	Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene, 2018, 37, 4385-4397.	5.9	21
39	An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. Gastroenterology, 2018, 155, 1985-1998.e5.	1.3	61
40	Notch inhibitor screening reveals an unexpected HES1 heterodimer. Journal of Biological Chemistry, 2018, 293, 8295-8296.	3.4	3
41	Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. Cancer Medicine, 2018, 7, 4639-4649.	2.8	12
42	Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. Journal of Clinical Investigation, 2018, 128, 4472-4484.	8.2	105
43	Abstract 3913: Selective targeting of circulating tumor cells with agonistic EphA2 ligand. Cancer Research, 2018, 78, 3913-3913.	0.9	3
44	Abstract 1267: A novel mitochondria-based targeting to restore therapeutic responsiveness in cisplatin- and geftinib-resistant human lung cancer cells. , 2018, , .		0
45	Abstract 5208: Monocyte-produced Chitinase-3-like 1 is a driver of metastatic behavior in prostate cancer patients. , 2018, , .		0
46	Abstract B086: Monocytes-produced Chitinase-3-like 1 is a driver of metastatic behavior in advanced prostate cancer patients. , 2018, , .		0
47	MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. Cancer Research, 2017, 77, 2306-2317.	0.9	119
48	Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2â€"WNT Signaling Axis. Cancer Research, 2017, 77, 1331-1344.	0.9	50
49	Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. Endocrinology, 2017, 158, 2255-2268.	2.8	22
50	FOXC1: an emerging marker and therapeutic target for cancer. Oncogene, 2017, 36, 3957-3963.	5.9	110
51	MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. Endocrine-Related Cancer, 2017, 24, R157-R172.	3.1	54
52	PD12-07 HISTONE DEACETYLASE INHIBITOR SUBEROYLANILIDE HYDROXAMIC ACID AMELIORATES HEMORRHAGIC CYSTITIS VIA DNA DAMAGE REPAIR GENE PATHWAYS. Journal of Urology, 2017, 197, .	0.4	0
53	Porphyromonas gingivalis-Derived Lipopolysaccharide Combines Hypoxia to Induce Caspase-1 Activation in Periodontitis. Frontiers in Cellular and Infection Microbiology, 2017, 7, 474.	3.9	50
54	S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/b-methionine adenosyltransferase 2A/2B axis. Oncotarget, 2017, 8, 78851-78869.	1.8	27

#	Article	IF	Citations
55	Modulation of cabozantinib efficacy by the prostate tumor microenvironment. Oncotarget, 2017, 8, 87891-87902.	1.8	14
56	Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases.. Journal of Clinical Oncology, 2017, 35, 5031-5031.	1.6	0
57	Role of EMT in Metastasis and Therapy Resistance. Journal of Clinical Medicine, 2016, 5, 17.	2.4	372
58	Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis. Scientific Reports, 2016, 6, 39257.	3.3	17
59	MP62-16 THE EXPLORATION OF THE ORDER IN THE HETEROGENEITY OF PROSTATE CANCER-ASSOCIATED STROMA ENVIRONMENT.. Journal of Urology, 2016, 195, .	0.4	0
60	MP24-08 EPIGENETIC REGULATION OF DNA DAMAGE REPAIR GENE 8-OXOGUANINE DNA GLYCOSYLASE (OGG1) IN THE PYROPTOSIS PATHWAYS OF HEMORRHAGIC CYSTITIS. Journal of Urology, 2016, 195, .	0.4	1
61	Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations. Molecular Cancer Research, 2016, 14, 374-384.	3.4	34
62	A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials, 2016, 91, 140-150.	11.4	68
63	Myeloid-specific TGF-Î² signaling in bone promotes basic-FGF and breast cancer bone metastasis. Oncogene, 2016, 35, 2370-2378.	5.9	46
64	A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. Journal of Clinical Oncology, 2016, 34, 208-208.	1.6	1
65	A phase 2 study of cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. Journal of Clinical Oncology, 2016, 34, e16552-e16552.	1.6	0
66	Abstract 177: Src family kinase Fyn promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. , 2016, , .		0
67	Abstract LB-266: Large oncosomes reprogram prostate fibroblasts toward a pro-angiogenic phenotype. , 2016, , .		0
68	Abstract 2067: Attacking prostate cancer with a prodrug-doped cellular Trojan horse. , 2016, , .		1
69	Abstract LB-274: Microenvironment mediates the efficacy of Cabozantinib in prostate cancer. , 2016, , .		2
70	MP20-04 DNA DAMAGE REPAIR GENES REGULATE BLADDER INFLAMMATION. Journal of Urology, 2015, 193, .	0.4	0
71	Inflammation and Pyroptosis Mediate Muscle Expansion in an Interleukin-1Î² (IL-1Î²)-dependent Manner. Journal of Biological Chemistry, 2015, 290, 6574-6583.	3.4	45
72	Be resistant to apoptosis: a host factor from gingival fibroblasts. Cell Death and Disease, 2015, 6, e2009-e2009.	6.3	12

#	Article	IF	Citations
73	A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer. Phytotherapy Research, 2015, 29, 805-817.	5.8	68
74	SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Oncotarget, 2015, 6, 44072-44083.	1.8	29
75	A reciprocal role of prostate cancer on stromal DNA damage. Oncogene, 2014, 33, 4924-4931.	5.9	38
76	MP8-12 NICOTINAMIDE REGULATES BLADDER INFLAMMATION THROUGH EPIGENETIC MECHANISMS. Journal of Urology, 2014, 191, .	0.4	0
77	A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.. Journal of Clinical Oncology, 2014, 32, e16080-e16080.	1.6	0
78	Abstract 2868: Use of methionine metabolites in predicting recurrent prostate cancer affordably. , 2014, , .		0
79	Abstract 699: Mesenchymal stem cells (MSC) as cell-based vectors for PSA-activated proaerolysin to sites of prostate cancer. , 2014, , .		0
80	Mechanisms of hemorrhagic cystitis. American Journal of Clinical and Experimental Urology, 2014, 2, 199-208.	0.4	34
81	The E3ÂUbiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity. Cancer Cell, 2013, 23, 332-346.	16.8	132
82	Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells. Clinical Cancer Research, 2013, 19, 128-137.	7.0	53
83	Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle, 2013, 12, 3526-3536.	2.6	189
84	A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models. PLoS ONE, 2013, 8, e54918.	2.5	52
85	Loss of TGF-Î² Responsiveness in Prostate Stromal Cells Alters Chemokine Levels and Facilitates the Development of Mixed Osteoblastic/Osteolytic Bone Lesions. Molecular Cancer Research, 2012, 10, 494-503.	3.4	62
86	Metastatic Ability: Adapting to a Tissue Site Unseen. Cancer Cell, 2012, 22, 563-564.	16.8	6
87	Sabutoclax, a Mcl-1 Antagonist, Inhibits Tumorigenesis in Transgenic Mouse and Human Xenograft Models of Prostate Cancer. Neoplasia, 2012, 14, 656-IN24.	5.3	41
88	Understanding the role of stromal fibroblasts in cancer progression. Cell Adhesion and Migration, 2012, 6, 231-235.	2.7	89
89	Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease. American Journal of Pathology, 2012, 181, 1573-1584.	3.8	321
90	Loss of epithelial oestrogen receptor Î± inhibits oestrogenâ€stimulated prostate proliferation and squamous metaplasia via <i>in vivo</i> tissue selective knockout models. Journal of Pathology, 2012, 226, 17-27.	4.5	32

#	Article	IF	Citations
91	Modeling Transforming Growth Factor-ÃŸ Signaling in Cancer. , 2012, , 397-415.		0
92	Abstract 430: MiRNA profiling of prostate cancer cell-derived large oncosomes identifies a signature of invasion and metastasis. , 2012, , .		0
93	Mesenchymal Stem Cell Recruitment and Improved Bladder Function After Bladder Outlet Obstruction: Preliminary Data. Journal of Urology, 2011, 185, 1132-1138.	0.4	58
94	Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression. PLoS ONE, 2011, 6, e22486.	2.5	80
95	Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. Oncogene, 2011, 30, 167-177.	5.9	35
96	Altered TGF-Î² Signaling in a Subpopulation of Human Stromal Cells Promotes Prostatic Carcinogenesis. Cancer Research, 2011, 71, 1272-1281.	0.9	158
97	Role for Stromal Heterogeneity in Prostate Tumorigenesis. Cancer Research, 2011, 71, 3459-3470.	0.9	80
98	Yes-Associated Protein Expression in Head and Neck Squamous Cell Carcinoma Nodal Metastasis. PLoS ONE, 2011, 6, e27529.	2.5	69
99	Abstract 527: Loss of TGF-Î² responsiveness in stromal cells of the prostate facilitates early prostate cancer bone lesion development. , 2011, , .		0
100	Abstract 391: Inflammatory mediators of prostate cancer metastasis. , 2011, , .		0
101	Bone Marrow Derived Mesenchymal Stem Cells Incorporate into the Prostate during Regrowth. PLoS ONE, 2010, 5, e12920.	2.5	48
102	Could stroma contribute to field cancerization?. Medical Hypotheses, 2010, 75, 26-31.	1.5	31
103	Dermal Transforming Growth Factor-Î² Responsiveness Mediates Wound Contraction and Epithelial Closure. American Journal of Pathology, 2010, 176, 98-107.	3.8	89
104	Abstract 1015: Head and neck cancer expression of YAP65: A novel oncogene. , 2010, , .		0
105	Autoimmune pancreatitis results from loss of TGFÂ signalling in S100A4-positive dendritic cells. Gut, 2009, 58, 1267-1274.	12.1	46
106	Identification of extracellular Î'â€‹catenin accumulation for prostate cancer detection. Prostate, 2009, 69, 411-418.	2.3	101
107	Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-Î² signaling. Differentiation, 2009, 77, 95-102.	1.9	37
108	Bladder Stromal Loss of Transforming Growth Factor Receptor II Decreases Fibrosis After Bladder Obstruction. Journal of Urology, 2009, 182, 1775-1780.	0.4	32

#	Article	IF	Citations
109	Recruitment of Bone Marrow Derived Cells to the Bladder After Bladder Outlet Obstruction. Journal of Urology, 2009, 182, 1769-1774.	0.4	28
110	Prostate tumor progression is mediated by a paracrine TGF-Î²/Wnt3a signaling axis. Oncogene, 2008, 27, 7118-7130.	5.9	145
111	Gene Targeting to the Stroma of the Prostate and Bone. Differentiation, 2008, 76, 606-623.	1.9	14
112	Nicotinic Signaling Ameliorates Acute Bladder Inflammation Induced by Protamine Sulfate or Cyclophosphamide. Journal of Urology, 2008, 179, 2440-2446.	0.4	22
113	Role of Nicotinic and Estrogen Signaling during Experimental Acute and Chronic Bladder Inflammation. American Journal of Pathology, 2008, 172, 59-67.	3.8	24
114	Temporal-Spatial Protein Expression in Bladder Tissue Derived From Embryonic Stem Cells. Journal of Urology, 2008, 180, 1784-1789.	0.4	28
115	Directed Differentiation of Bone Marrow Derived Mesenchymal Stem Cells Into Bladder Urothelium. Journal of Urology, 2008, 180, 1778-1783.	0.4	64
116	Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy. Clinical Cancer Research, 2008, 14, 7790-7797.	7.0	51
117	Stromal Transforming Growth Factor-Î² Signaling Mediates Prostatic Response to Androgen Ablation by Paracrine Wnt Activity. Cancer Research, 2008, 68, 4709-4718.	0.9	104
118	The Nuclear Factor-ÎºB Pathway Controls the Progression of Prostate Cancer to Androgen-Independent Growth. Cancer Research, 2008, 68, 6762-6769.	0.9	178
119	Transforming Growth Factor-Î² (TGF-Î²) and TGF-Î²â€“Associated Kinase 1 Are Required for R-Rasâ€“Mediated Transformation of Mammary Epithelial Cells. Cancer Research, 2008, 68, 6224-6231.	0.9	16
120	TGF-Î² Signaling in Fibroblastic Cells and Oncogenesis. , 2008, , 185-198.		1
121	Signaling Pathways Regulating TC21-induced Tumorigenesis. Journal of Biological Chemistry, 2007, 282, 27713-27720.	3.4	31
122	Directed differentiation of embryonic stem cells into bladder tissue. Developmental Biology, 2007, 304, 556-566.	2.0	93
123	Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine. Biochemical and Biophysical Research Communications, 2007, 353, 829-834.	2.1	91
124	Urothelial Inhibition of Transforming Growth Factor-Î² in a Bladder Tissue Recombination Model. Journal of Urology, 2007, 178, 1643-1649.	0.4	4
125	Bladder tissue formation from cultured bladder urothelium. Developmental Dynamics, 2006, 235, 2795-2801.	1.8	22
126	Essential Role of Smad3 in Angiotensin IIâ€“Induced Vascular Fibrosis. Circulation Research, 2006, 98, 1032-1039.	4.5	219

#	Article	IF	Citations
127	Transforming Growth Factor-Î² Promotes Invasion in Tumorigenic but not in Nontumorigenic Human Prostatic Epithelial Cells. Cancer Research, 2006, 66, 8007-8016.	0.9	111
128	Loss of TGF-Î² type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-Î±-, MSP- and HGF-mediated signaling networks. Oncogene, 2005, 24, 5053-5068.	5.9	252
129	STROMAL HYPERPLASIA IN MALE BLADDERS UPON LOSS OF TRANSFORMING GROWTH FACTOR-Î² SIGNALING IN FIBROBLASTS. Journal of Urology, 2005, 174, 1704-1707.	0.4	18
130	Tumorâ€“stroma interactions. Current Opinion in Genetics and Development, 2005, 15, 97-101.	3.3	408
131	Linking TGF-beta-mediated Cdc25A Inhibition and Cytoskeletal Tegulation through RhoA/p160ROCK Signaling. Cell Cycle, 2004, 3, 406-408.	2.6	7
132	Stromal fibroblasts in cancer initiation and progression. Nature, 2004, 432, 332-337.	27.8	2,032
133	TGF-ÃŸ Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia. Science, 2004, 303, 848-851.	12.6	1,279
134	The Loss of TGF-Î² Signaling Promotes Prostate Cancer Metastasis. Neoplasia, 2003, 5, 267-277.	5.3	93
135	Transgenic Mice Expressing a Dominant-Negative Mutant Type II Transforming Growth Factor-Î² Receptor Exhibit Impaired Mammary Development and Enhanced Mammary Tumor Formation. American Journal of Pathology, 2003, 163, 1539-1549.	3.8	120
136	Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Research, 2003, 5, R187-98.	5.0	112
137	TGF-Î²-induced RhoA and p160 ^{ROCK} activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15548-15553.	7.1	114
138	Transforming Growth Factor-Î²1 Mediates Epithelial to Mesenchymal Transdifferentiation through a RhoA-dependent Mechanism. Molecular Biology of the Cell, 2001, 12, 27-36.	2.1	962
139	Integrin Î²1 Signaling Is Necessary for Transforming Growth Factor-Î² Activation of p38MAPK and Epithelial Plasticity. Journal of Biological Chemistry, 2001, 276, 46707-46713.	3.4	354
140	Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor Î²-mediated Epithelial to Mesenchymal Transition and Cell Migration. Journal of Biological Chemistry, 2000, 275, 36803-36810.	3.4	873
141	Identification of Ionizable Amino Acid Residues on the Extracellular Domain of the Lutropin Receptor Involved in Ligand Binding. Endocrinology, 1999, 140, 4558-4563.	2.8	10
142	Surface retention of an inactivating lutropin receptor mutant in exoloop 3. Molecular and Cellular Biochemistry, 1998, 187, 221-227.	3.1	3
143	hCG-receptor binding and transmembrane signaling. Molecular and Cellular Endocrinology, 1996, 125, 55-64.	3.2	32